John McDermott is Vice President of Scientific Consulting at Quotient Sciences. John leads Quotient Sciences' global drug development consulting, research fellows, modeling & simulation, and client services teams. He provides scientific expertise that helps Quotient Sciences' commercial and operational teams maximize growth and ensure client programs' success. 

John has over 25 years of experience in pharmaceutical sciences with prior roles at companies including Rhone Poulenc Rorer and Covance (later acquired by LabCorp). He joined Pharmaceutical Profiles in 2001, which, following a series of M&A and organic growth, was rebranded as Quotient Sciences in 2017.

John has been central to the development of Quotient Sciences Translational Pharmaceutics^®, the Company's flagship drug development platform. This platform integrates formulation development, on-demand GMP drug product manufacturing, and healthy volunteer clinical testing to deliver time and cost efficiencies in small molecule and oral peptide drug programs and applications.

John has significant experience in scintigraphy imaging studies for oral and inhaled dosage forms, including the development and validation of radiolabeling methods. He holds a Bachelor of Science degree in Chemistry, with a focus on Analytical Chemistry, from the University of Hull.